{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:38:32Z","timestamp":1758400712842},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11255-017-1774-9","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T08:35:49Z","timestamp":1514882149000},"page":"905-909","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients"],"prefix":"10.1007","volume":"50","author":[{"given":"Dengpiao","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naijing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"issue":"2","key":"1774_CR1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","volume":"17","author":"M Taniguchi","year":"2013","unstructured":"Taniguchi M, Fukagawa M, Fujii N et al (2013) Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 17(2):221\u2013228","journal-title":"Ther Apher Dial"},{"issue":"8","key":"1774_CR2","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol JASN 15(8):2208\u20132218","journal-title":"J Am Soc Nephrol JASN"},{"issue":"4","key":"1774_CR3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbertshearon TE, Levin NW et al (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31(4):607","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1774_CR4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1681\/ASN.2008060609","volume":"20","author":"T Isakova","year":"2009","unstructured":"Isakova T, Guti\u00e9rrez OM, Chang Y et al (2009) Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol JASN 20(2):388","journal-title":"J Am Soc Nephrol JASN"},{"issue":"4","key":"1774_CR5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","volume":"62","author":"IB Di","year":"2013","unstructured":"Di IB, Molony D, Bell C et al (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62(4):771","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1774_CR6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P et al (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62(1):245\u2013252","journal-title":"Kidney Int"},{"issue":"6","key":"1774_CR7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","volume":"51","author":"W Qunibi","year":"2008","unstructured":"Qunibi W, Muenz LR (2008) A, 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51(6):952\u2013965","journal-title":"Am J Kidney Dis"},{"key":"1774_CR8","first-page":"1","volume":"21","author":"F Koiwa","year":"2016","unstructured":"Koiwa F, Terao A (2016) Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol 21:1","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1774_CR9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","volume":"74","author":"P Geisser","year":"2010","unstructured":"Geisser P, Philipp E (2010) PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74(1):4","journal-title":"Clin Nephrol"},{"issue":"2","key":"1774_CR10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","volume":"8","author":"RP W\u00fcthrich","year":"2013","unstructured":"W\u00fcthrich RP, Chonchol M, Covic A et al (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol CJASN 8(2):280","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"1","key":"1774_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"3","key":"1774_CR12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M et al (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86(3):638","journal-title":"Kidney Int"},{"issue":"6","key":"1774_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","volume":"30","author":"F J\u00fcrgen","year":"2015","unstructured":"J\u00fcrgen F, Covic AC, Markus K et al (2015) Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 30(6):1037\u20131046","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1774_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/nep.12891","volume":"22","author":"F Koiwa","year":"2017","unstructured":"Koiwa F, Yokoyama K, Fukagawa M et al (2017) Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology 22(4):293\u2013300","journal-title":"Nephrology"},{"issue":"6","key":"1774_CR15","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00041552-200111000-00003","volume":"10","author":"GA Block","year":"2001","unstructured":"Block GA (2001) Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 10(6):741","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"1774_CR16","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1093\/ndt\/gfr591","volume":"26","author":"JB Cannataandia","year":"2011","unstructured":"Cannataandia JB, Romangarcia P, Hruska K (2011) The connections between vascular calcification and bone health. Nephrol Dial Transplant 26(11):3429","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1774_CR17","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London GM, Marty C, Marchais SJ et al (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol JASN 15(7):1943","journal-title":"J Am Soc Nephrol JASN"},{"issue":"1","key":"1774_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJNRD.S78040","volume":"9","author":"V Cernaro","year":"2016","unstructured":"Cernaro V, Santoro D, Lacquaniti A et al (2016) Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renov Dis 9(1):11","journal-title":"Int J Nephrol Renov Dis"},{"issue":"6","key":"1774_CR19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M et al (2009) Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol CJASN 4(6):1089","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"11","key":"1774_CR20","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","volume":"29","author":"S Wang","year":"2014","unstructured":"Wang S, Alfieri T, Ramakrishnan K et al (2014) Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant 29(11):2092","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1774_CR21","first-page":"525","volume":"23","author":"MD Arenas","year":"2010","unstructured":"Arenas MD, Malek T, Gil MT et al (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 23(5):525","journal-title":"J Nephrol"},{"issue":"1","key":"1774_CR22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","volume":"20","author":"RB Fissell","year":"2016","unstructured":"Fissell RB, Karaboyas A, Bieber BA et al (2016) Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemod Int 20(1):38\u201349","journal-title":"Hemod Int"},{"issue":"1","key":"1774_CR23","first-page":"10","volume":"40","author":"S Chan","year":"2017","unstructured":"Chan S, Au K, Francis RS et al (2017) Phosphate binders in patients with chronic kidney disease. Aust Prescr 40(1):10\u201314","journal-title":"Aust Prescr"},{"issue":"2","key":"1774_CR24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/jgh.13458","volume":"32","author":"CJ Grant","year":"2017","unstructured":"Grant CJ, Harrison LE, Hoad CL et al (2017) Patients with chronic kidney disease have abnormal upper gastro-intestinal tract digestive function: a study of uremic enteropathy. J Gastroenterol Hepatol 32(2):372\u2013377","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"1774_CR25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3182999d8d","volume":"37","author":"BJ Swanson","year":"2013","unstructured":"Swanson BJ, Limketkai BN, Liu TC et al (2013) Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. Am J Surg Pathol 37(11):1686","journal-title":"Am J Surg Pathol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1774-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1774-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T08:23:19Z","timestamp":1525422199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1774-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1774"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1774-9","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]}}}